EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group

Maxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi iD, Riccardo Autorino iD, Gabriele Bignante iD, Chandru Sundaram, Daniel Sidhom, Ithaar H Derweesh, Dhruv Puri iD, Vitaly Margulis, Benjamin Popokh iD, Firas Abdollah iD und 27 weitere

Cancers · 25.06.2025 · 17 (13) · 2144

DOI: 10.3390/cancers17132144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 25.06.2025. Verfasst von Maxwell Otiato und 38 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Urology, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA 90089, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: The impact of adjuvant immunotherapy (IO) on the prognosis of patients with upper tract urothelial carcinoma (UTUC) remains unclear. This study examines the association of adjuvant IO with oncologic outcomes in patients with high-risk UTUC.

Methods

This retrospective study reviewed patients with high-risk UTUC treated with adjuvant IO using the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) database. Propensity-score-matched analysis (nearest-neighbor algorithm, caliper 0.1) was conducted to compare patients receiving adjuvant IO versus those who did not, with matching based on pathologic T and N category and receipt of neoadjuvant chemotherapy. Associations between adjuvant IO and urothelial recurrence-free survival (URFS), non-urothelial recurrence-free survival (NRFS), and overall survival (OS) were estimated using a Cox proportional hazards model.

Results

Seventy-five patients received adjuvant IO following nephroureterectomy (median four cycles, including eleven (14.7%) nivolumab, thirty-one (41.3%) pembrolizumab, four (5.3%) atezolizumab, and twenty-nine (38.6%) other agents. These patients were matched to 68 patients without adjuvant therapy. Median follow-up times were 17 (IQR, 10–29) months and 20 (9–44) months for IO and no adjuvant therapy, respectively. Multivariable analysis revealed that adjuvant IO was not associated with URFS, NRFS, or OS. Pathologic nodal involvement (HR 7.52, p < 0.001) was the only independent predictor of worse OS.

Conclusions

In this real-world retrospective data set, adjuvant IO does not have an impact on oncologic outcomes of UTUC patients following extirpative surgery.

Schlagwörter

Stichwörter der Autor:innen

immunotherapynephroureterectomyoutcomesupper tract urothelial carcinoma

Autor:innen und Institutionen

  • Institute of Urology, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA 90089, USA.
  • Department of Urology, Rush University, Chicago, IL 60612, USA.
  • Department of Urology, Indiana University, Indianapolis, IN 47405, USA.
  • Department of Urology, UC San Diego School of Medicine, La Jolla, CA 92093, USA.
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI 48202, USA.

ORCID-Profile: Alireza Ghoreifi, Riccardo Autorino, Gabriele Bignante, Dhruv Puri, Benjamin Popokh, Firas Abdollah, Giuseppe Simone, Gabriele Tuderti, Ahmed Eraky, Enrico N Checcucci, Alessandro Antonelli, Alessandro Veccia, Soroush Rais-Bahrami, Alireza Dehghanmanshadi, Roberto Contieri, Saum Ghodoussipour

Zitieren

APA

Otiato, M., Moghaddam, F. S., Ghoreifi, A., Autorino, R., Bignante, G., Sundaram, C., Sidhom, D., Derweesh, I. H., Puri, D., Margulis, V., Popokh, B., Abdollah, F., Stephens, A., Ferro, M., Simone, G., Tuderti, G., Mehrazin, R., Eraky, A., Gonzalgo, M., …, & Djaladat, H. (2025). Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group. Cancers, 17(13), 2144. https://doi.org/10.3390/cancers17132144

Vancouver

Otiato M, Moghaddam FS, Ghoreifi A, Autorino R, Bignante G, Sundaram C, et al. Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group. Cancers. 2025;17(13):2144. doi:10.3390/cancers17132144

BibTeX
@article{Otiato2025,
  author = {Otiato, Maxwell and Moghaddam, Farshad Sheybaee and Ghoreifi, Alireza and Autorino, Riccardo and Bignante, Gabriele and Sundaram, Chandru and Sidhom, Daniel and Derweesh, Ithaar H and Puri, Dhruv and Margulis, Vitaly and Popokh, Benjamin and Abdollah, Firas and Stephens, Alex and Ferro, Matteo and Simone, Giuseppe and Tuderti, Gabriele and Mehrazin, Reza and Eraky, Ahmed and Gonzalgo, Mark and Nativ, Omar Falik and Wu, Zhenjie and Porpiglia, Francesco and Checcucci, Enrico N and Correa, Andres and Lee, Randall and Antonelli, Alessandro and Veccia, Alessandro and Rais-Bahrami, Soroush and Dehghanmanshadi, Alireza and Singla, Nirmish and Brönimann, Stephan and Perdonà, Sisto and Contieri, Roberto and Yoshida, Takashi and Porter, James and Ghodoussipour, Saum and Lambertini, Luca and Minervini, Andrea and Djaladat, Hooman},
  title = {Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {13},
  pages = {2144},
  doi = {10.3390/cancers17132144}
}
Kostenlos starten →